April Super Saver • 20% OFF EVERYTHING • Shop Now

1st Edition

Cancer Biomarkers Minimal and Noninvasive Early Diagnosis and Prognosis

    ISBN 9781138076808
    951 Pages 128 B/W Illustrations
    Published March 31, 2017 by CRC Press

    United States Flag Free Shipping (6-12 Business Days)
    shipping options

    Original Price $125.00
    Sale Price USD $100.00
    ISBN 9781466584280
    951 Pages 128 B/W Illustrations
    Published January 30, 2014 by CRC Press

    United States Flag Free Shipping (6-12 Business Days)
    shipping options

    Original Price $325.00
    Sale Price USD $260.00
    Continue Shopping

     

    Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers.

    It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information.

    Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single Volume

    The book details the general and technical aspects of noninvasive cancer markers. It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers.

    Emphasizes the Importance of Volatile Markers in Early Cancer Diagnosis

    • Presents noninvasive early molecular markers in urological cancers
    • Describes gynecological and endocrine cancer markers
    • Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers
    • Addresses hematological malignancies 
    • Contains information on noninvasive molecular markers in myelodysplastic syndromes, acute myeloid leukemia, Hodgkin’s lymphoma, and multiple myeloma
    • Provides comprehensive information on diagnostic and prognostic biomarkers in cutaneous melanoma

    This text considers molecular technologies for biomarker development, noninvasive or minimally invasive sources of molecular markers, and quality control and ethical issues in cancer biomarker discovery.

    Part I General and Technical Aspects

    Quality Control and Ethical Issues of Cancer Biomarker Discovery

    Anjana Munshi and Vandana Sharma

    Imaging Techniques in Cancer Diagnosis

    Mohamed Abd El-Salam, Sonia Reda, Salwa Lotfi, Tamar Refaat, and Eman El-Abd

    Role of PET in Cancer Diagnosis

    Silvia Taralli, Antonella Stefanelli, and Giorgio Treglia

    Innovative Tools for Early Detection of Cancer

    Ali Tiss, Amal Hasan, Abdelkrim Khadir, Mohammed Dehbi, and Said Dermime

    Noninvasive Nanodiagnostics for Cancer

    Sandhiya Selvarajan, Melvin George, and Suresh Kumar

    Mitochondrial DNA in Early Cancer Diagnosis and Screening

    Mukesh Verma, Neelesh Agarwal, and Mudit Verma

    Circulating miRNA Biomarkers in Various Solid Cancers

    Martina Redova, Hana Mlcochova, and Ondrej Slaby

    Stem Cell Biomarkers in Early Diagnosis, Prognosis, and Therapy of Cancer

    Dipali Dhawan and Harish Padh

    Salivary Biomarkers in Early Diagnosis and Monitoring of Cancer

    Saroj K Basak and Eri S Srivatsan

    Part II Brain and Head and Neck Cancers

    Biomarkers for Brain Gliomas

    Yusuf Izci

    Noninvasive Biomarkers in Head and Neck Squamous Cell Carcinoma

    Anand Kumar, Mumtaz Ahmad Ansari, and Vivek Srivastava

    Biological Markers in Oral Squamous Cell Carcinoma

    Mario Pérez-Sayáns García, Danielle Resende Camisasca, Abel García García, Simone de Queiroz Chaves Lourenço, and Anastasios Markopoulos

    Part III Gastrointestinal Cancers

    Biomarkers for Gastric Cancer and the Related Premalignant Conditions

    Marcis Leja, Jan Bornschein, Juozas Kupcinskas, and Peter Malfertheiner

    Biomarkers in Esophageal Adenocarcinoma

    Simon JW Monkhouse, J Muhlschlegel, and H Barr

    Biomarkers for Diagnosis and Metastasis of Hepatocellular Carcinoma

    Dengfu Yao, Min Yao, Xiaodi Yan, Li Wang, and Zhizhen Dong

    Noninvasive Early Markers in Gallbladder Cancer

    Mumtaz Ahmad Ansari, Ruhi Dixit, and Vijay Kumar Shukla

    Noninvasive Early Markers in Pancreatic Cancer

    Aleksandra Nikolic

    Part IV Lung Cancer and Mesothelioma

    Noninvasive Early Markers in Lung Cancer

    Mukesh Verma, Debmalya Barh, and Neha Jain

    Exhaled Volatile Organic Compounds as Noninvasive Early Molecular Markers

    in Lung Cancer: Bridging the Gap from Bench to Bedside

    Meggie Hakim, Ulrike Tisch, Michael Unger, and Hossam Haick

    Part V Urological Cancers

    Noninvasive Early Molecular Biomarkers in Kidney Cancer

    Brian W Cross, Jonathan Huang, and Viraj A Master

    Novel Oncomarkers Used for Earlier Detection of Bladder Carcinoma

    Miroslava Bilecová-Rabajdová, Peter Urban, Mária Mareková, and Vincent Nagy

    Screening for Prostate Cancer: New Markers and Future Aspects

    Nigel P Murray

    Part VI Gynecological and Endocrine Cancers

    Early Biomarkers in Breast Cancer

    Ruchika Kaul-Ghanekar, Snehal Suryavanshi, and Prerna Raina

    Noninvasive Biomarkers in Ovarian Cancer

    Sharon A O’Toole, Eugen Ancuta, Ream Langhe, Dolores J Cahill, Mairead Murphy,

    Cara Martin, Lynda McEvoy, Cathy Spillane, Orla Sheils, Emmanuel Petricoin,

    Lance Liotta, and John J O’Leary

    Early Markers for Neoplastic Lesions of the Uterine Cervix

    Pablo Conesa-Zamora

    Biomarkers in Diagnosis of Papillary Thyroid Carcinoma

    Marisa Cañadas-Garre, Nuria Muñoz Pérez, Jesús Maria Villar del Moral, José Antonio Ferrón Orihuela, and José Manuel Llamas-Elvira

    Biomolecular Markers for Improving Management of Follicular and Medullary

    Thyroid Cancer

    Umut Mousa, Cuneyd Anil, Serife Mehlika Isıldak, Alptekin Gursoy, and Angelo Carpi

    Part VII Hematological Cancers

    Biomarkers in Myelodysplastic Syndrome

    Néstor L López Corrales and Vasco Ariston de Carvalho Azevedo

    Markers for Diagnosis, Prognosis, and Therapy of Acute Myeloid Leukemia

    Ota Fuchs

    Biomarkers in Hodgkin’s Lymphoma

    Esin Demir, Burak Yılmaz, Mehmet Gunduz, and Esra Gunduz

    Multiple Myeloma and Evolution of Novel Biomarkers and Therapies

    Michael Byrne, Joseph Katz, and Jan S Moreb

    Part VIII Melanoma

    Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma

    Eijun Itakura and Alistair J Cochran

    Index

    Biography

    Debmalya Barh (MSc, MTech, MPhil, PhD, PGDM) is the founder and president of the Institute of Integrative Omics and Applied Biotechnology (IIOAB), India. He is a consultant biotechnologist and an active researcher in integrative omics–based biomarkers, targeted drug discovery, and personalized medicine in cancer, neurodisorders, and cardiovascular, infectious, and metabolic diseases. He works with nearly 400 esteemed researchers from 30–35 countries and he has more than 100 high-impact publications. He has edited ten books in the field of omics. He also serves as an editorial and review board member for several highly respected international journals.

    Dr. Angelo Carpi is a clinical professor of medicine at the Pisa University Medical School, Pisa, Italy. He received his MD and postgraduate diplomas in internal medicine and nuclear medicine from the University of Pisa and his diploma of qualification on peptide hormones from the Collegio Medico Giuridico-Scuola Normale Superiore and the Scuola Superiore Sant’Anna, Pisa, Italy. His clinical practice and research included thyroid and breast tumors. He has authored about 300 publications included in PubMed. He is a member of the editorial boards of international journals such as Biomedicine & Pharmacotherapy and Frontiers in Bioscience.

    Dr. Mukesh Verma is a program director and chief in the Methods and Technologies Branch (MTB), Epidemiology and Genomics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Verma received his MSc from Pantnagar University and his PhD from Banaras Hindu University. He did postdoctoral research at George Washington University and was a faculty member at Georgetown University. He has published 128 research articles, book chapters, and reviews, and has edited three books in the field of cancer epigenetics and epidemiology.

    Mehmet Gunduz, MD, PhD, is a professor of otolaryngology and medical genetics, Faculty of Medicine, Turgut Ozal University, Turkey. He graduated from Medical School Hacettepe University in 1990, and completed his residency in otolaryngology at the same university. He received his PhD from Okayama University and Wakayama Medical University, Japan, and is medical board certified from both the Turkish and Japanese certification authorities. One of the pioneers in identifying ING family tumor suppressors, Dr. Gunduz has contributed to more than 150 international publications, 3,000 citations, several book chapters, and over 200 presentations in national and international conferences.

    "This book gathers a unique collection of information on cancer biomarkers that will be an invaluable reference for those in the field. It is particularly commendable for its extensive use of tables listing biomarkers, their clinical applications, and the state of clinical validation each has received. By bringing this information together into a single book, the authors provide essential background for the formulation of new diagnostic approaches to individual cancer types not available elsewhere. Weighted numerical score: 81 - 3 stars."
    —Steven Smith, Ph.D, City of Hope, Duarte, California, USA, from Doody's Book Reviews

    We offer free standard shipping on every order across the globe.

    Free Shipping (6-12 Business Days)